

## APPOINTMENT OF CHIEF FINANCIAL OFFICER

**MELBOURNE (AUSTRALIA) 13 July 2020:** Invion Limited (ASX: IVX) ("Invion" or "Company") is pleased to announce the appointment of Melanie Leydin as chief financial officer with immediate effect.

Ms Leydin is a member of the Institute of Chartered Accountants, Fellow of the Governance Institute of Australia and is a Registered Company Auditor.

She brings extensive experience in public company responsibilities to Invion that spans over 25 years and has an established track record in areas such as statutory financial reporting, financial forecasting and budgets, internal controls, ASX and ASIC compliance, corporate governance and shareholder relations.

Since February 2000, Ms Leydin has been the principal of chartered accounting firm, Leydin Freyer. The practice provides outsourced accounting and company secretarial services to public and private companies across a host of industries, including but not limited to the bioscience, biotechnology, health sectors and technology.

Ms Leydin graduated from Swinburne University with a Bachelor of Business majoring in Accounting and Corporate Law and became a Chartered Accountant in 1999.

Invion Managing Director and Chief Executive, Craig Newton, said "Melanie brings a wealth of experience in managing listed biotechnology companies and will be an invaluable resource to Invion."

---

### Investor enquiries

Managing Director & CEO, Craig Newton<sup>1</sup>  
T: +61 3 9081 6005  
E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

### Media enquiries

Brendon Lau  
T: 0409 341 613  
E: [brendon@vantagepointpartners.com.au](mailto:brendon@vantagepointpartners.com.au)

### About Invion

Invion is a life-science company that is leading the global research and development of Photosoff™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoff™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). For further information please contact [investor@inviongroup.com](mailto:investor@inviongroup.com).

### About Photodynamic Therapy (PDT)

Invion is developing Photosoff™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.

---

<sup>1</sup> This announcement has been authorised for release by MD & CEO, Craig Newton